Related Experiment Video
Updated: Apr 11, 2026
05:53
Measuring Frailty in HIV-infected Individuals. Identification of Frail Patients is the First Step to Amelioration and Reversal of Frailty
Published on: July 24, 2013
17.2K
How common is frailty in older Australians?
Imaina Widagdo1, Nicole Pratt1, Mary Russell2
1Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, Australia.
Australasian Journal on Ageing
|June 4, 2015
Summary
The prevalence of frailty in older Australians varies significantly depending on the measurement tool used. Researchers and clinicians should be aware that different frailty measures identify distinct populations.
Area of Science:
- Gerontology
- Public Health
- Epidemiology
Background:
- Frailty is a significant geriatric syndrome associated with adverse health outcomes in older adults.
- Accurate assessment of frailty prevalence is crucial for targeted interventions and resource allocation.
- Existing frailty assessment tools vary, potentially leading to discrepancies in prevalence estimates.
Purpose of the Study:
- To determine the prevalence of frailty in a cohort of older Australians.
- To compare the prevalence estimates derived from four distinct frailty assessment measures.
- To evaluate the agreement between unidimensional and multidimensional frailty assessment tools.
Main Methods:
- Utilized data from 2087 participants in the Australian Longitudinal Study of Ageing.
- Assessed frailty using two unidimensional measures: Frailty Phenotype and Simplified Frailty Phenotype.
- Assessed frailty using two multidimensional measures: Frailty Index and Prognostic Frailty Score.
Main Results:
- Multidimensional measures identified substantially higher frailty prevalence (17.5% and 49.4%) compared to unidimensional measures (2% and 8.8%).
- There was minimal agreement between the four frailty measures, with only 0.5% of participants classified as frail by all measures.
- Significant variability in frailty prevalence was observed based on the chosen assessment tool.
Conclusions:
- The apparent prevalence of frailty in older Australians is highly dependent on the specific measurement tool employed.
- Clinicians and researchers must recognize that different frailty measures may identify different subgroups of older individuals as frail.
- Awareness of these discrepancies is essential for accurate clinical assessment and research interpretation in gerontology.
Related Concept Videos
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
331
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
331
01:30Development of Human Microbiota
43
The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
43
01:15Drug Dosing: Geriatric Patients
360
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
360
01:29Bone Disorders
8.7K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.7K
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
341
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
341
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
326
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
326